retatrutide fat loss clinical trial results Weight Results:Trial Data and FDA Status New GLP-3 drug significantly slashes

A GIP receptor agonist exhibits beta-cell anti-apoptotic actions in rat models of diabetes resulting in improved beta-cell function and glycemic control

Patients who are pregnant, nursing, or have certain conditions (such as pancreatitis, gallbladder disease, or thyroid cancer) may not be eligible

Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing

Eating more fibre, lean protein, healthy fats, and water-rich fruits and vegetables can also increase GLP-1 levels naturally, supporting weight loss

GLP-1 stands for glucagon-like peptide-1, which is a hormone made in your small intestines

Retatrutide is an investigational drug and not for diagnostic or therapeutic use in humans